Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.

Riccardo Riccardi, Birgit Geoerger, Julia Chisholm, Marie-Cecile Le Deley, Jean-Claude Gentet, Christian Michel Zwaan, Nathalie Dias, Timothy Jaspan, Kieran Mc Hugh, Dominique Couanet, Sharon Hain, Annick Devos, Joachim Boos, Didier Frappaz, Pierre Leblond, Isabelle Aerts, Gilles Vassal

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

30 Citazioni (Scopus)

Abstract

AIM: To assess objective response rates after 4 cycles of gemcitabine in combination with oxaliplatin in children and adolescents with relapsed or refractory solid tumours. METHODS: This multicentre, non-randomised Phase II study included five strata: neuroblastoma, osteosarcoma, medulloblastoma and other CNS tumours strata with two-stage Simon designs and a miscellaneous, extra-cranial solid tumour stratum with descriptive design. Eligibility criteria included: age 6 months to 21 years; measurable, relapsed or refractory solid malignancy; no more than one previous salvage therapy. Gemcitabine was administered intravenously at 1000 mg/m(2) over 100 min followed by oxaliplatin at 100mg/m(2) over 120 min on Day 1 of a 14-d cycle. Tumour response was assessed every 4 cycles according to WHO criteria. RESULTS: Ninety-three out of 95 patients enrolled in 25 centres received treatment: 12 neuroblastoma; 12 osteosarcoma; 14 medulloblastoma; 13 other CNS tumours and 42 miscellaneous non-CNS solid tumours. Median age was 11.7 years (range, 1.3-20.8 years). Tumour control (CR+PR+SD) at 4 cycles was obtained in 30/93 evaluable patients (32.3%; 95% confidence interval (CI), 22.9-42.7%), including four PR: 1/12 patients with osteosarcoma, 1/12 with medulloblastoma, 1/12 with rhabdomyosarcoma and 1/4 with other sarcoma. Five out of 12 eligible patients with neuroblastoma experienced stable disease. During a total of 481 treatment cycles (median 4, range 1-24 per patient), the most common treatment-related toxicities were haematologic (leukopenia, neutropenia, thrombocytopenia) and neurological (dysesthesia, paresthesia). CONCLUDING STATEMENT: The gemcitabine-oxaliplatin combination administered in a bi-weekly schedule has acceptable safety profile with limited activity in children with relapsed or refractory solid tumours.
Lingua originaleEnglish
pagine (da-a)230-238
Numero di pagine9
RivistaEuropean Journal of Cancer
Volume47
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • ITCC
  • gemcitabine
  • oxaliplatin
  • pediatric solid tumors

Fingerprint Entra nei temi di ricerca di 'Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.'. Insieme formano una fingerprint unica.

Cita questo